menu
    • menu
    [{"orgOrder":0,"company":"PEP-Therapy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"PEP-010","moa":"Caspase-9\/PP2A interaction","graph1":"Oncology","graph2":"Phase I","graph3":"PEP-Therapy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PEP-Therapy \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PEP-Therapy \/ Inapplicable"},{"orgOrder":0,"company":"PEP-Therapy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Caspase-9\/PP2A interaction","graph1":"Oncology","graph2":"Phase I","graph3":"PEP-Therapy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PEP-Therapy \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PEP-Therapy \/ Inapplicable"},{"orgOrder":0,"company":"PEP-Therapy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Caspase-9\/PP2A interaction","graph1":"Oncology","graph2":"Phase I","graph3":"PEP-Therapy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PEP-Therapy \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PEP-Therapy \/ Inapplicable"},{"orgOrder":0,"company":"PEP-Therapy","sponsor":"Italian Angels for Growth","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Peptide","year":"2021","type":"Series A Financing","leadProduct":"PEP-010","moa":"Caspase-9\/PP2A interaction","graph1":"Oncology","graph2":"Phase I","graph3":"PEP-Therapy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PEP-Therapy \/ Italian Angels for Growth","highestDevelopmentStatusID":"6","companyTruncated":"PEP-Therapy \/ Italian Angels for Growth"},{"orgOrder":0,"company":"PEP-Therapy","sponsor":"Anaxago","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Peptide","year":"2021","type":"Series A Financing","leadProduct":"PEP-010","moa":"Caspase-9\/PP2A interaction","graph1":"Oncology","graph2":"Phase I","graph3":"PEP-Therapy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PEP-Therapy \/ Anaxago","highestDevelopmentStatusID":"6","companyTruncated":"PEP-Therapy \/ Anaxago"},{"orgOrder":0,"company":"PEP-Therapy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"PEP-010","moa":"Caspase-9\/PP2A interaction","graph1":"Oncology","graph2":"Phase I","graph3":"PEP-Therapy","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PEP-Therapy \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PEP-Therapy \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by PEP-Therapy

    Menu

    PEP-Therapy

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            PEP-Therapy

                            France arrow
                            AACR Annual meeting
                            Not Confirmed

                            PEP-Therapy

                            France arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PEP-010,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PEP-Therapy Wins FDA Orphan Drug Tag for PEP-010 in Pancreatic Cancer

                            Details : PEP-010, is currently undergoing early-stage clinical trials in combination with paclitaxel/gemcitabine for treating advanced/metastatic ovarian cancer & metastatic pancreatic ductal adenocarcinoma.

                            Product Name : PEP-010

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            March 17, 2025

                            Lead Product(s) : PEP-010,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            PEP-Therapy

                            France arrow
                            AACR Annual meeting
                            Not Confirmed

                            PEP-Therapy

                            France arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PEP-010,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PEP-Therapy Doses First Patients in Phase Ib Trial Of PEP-010 for Cancers

                            Details : PEP-010 is in early trials with Paclitaxel/Gemcitabine for advanced ovarian cancer and pancreatic ductal adenocarcinoma.

                            Product Name : PEP-010

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            April 25, 2024

                            Lead Product(s) : PEP-010,Gemcitabine,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            PEP-Therapy

                            France arrow
                            AACR Annual meeting
                            Not Confirmed

                            PEP-Therapy

                            France arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PEP-010

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Anaxago

                            Deal Size : $6.4 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            PEP-Therapy Extends Series-A Financing, Raising a Total of €5.4 Million

                            Details : PEP-010 is the first of a new class of therapeutic peptides based on PEP-Therapy's innovative Cell Penetrating & Interfering Peptide (CP&IP) technology.

                            Product Name : PEP-010

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            July 19, 2021

                            Lead Product(s) : PEP-010

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Anaxago

                            Deal Size : $6.4 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            PEP-Therapy

                            France arrow
                            AACR Annual meeting
                            Not Confirmed

                            PEP-Therapy

                            France arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PEP-010

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PEP-Therapy and Institut Curie Announce First Patients Dosed in Phase I Clinical Trial of PEP-010 for The Trea...

                            Details : PEP-010 is the first of a new class of therapeutic peptides based on PEP-Therapy’s innovative Cell Penetrating and Interfering Peptides (CP&IP) technology for the treatment of advanced solid tumors.

                            Product Name : PEP-010

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            May 10, 2021

                            Lead Product(s) : PEP-010

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            PEP-Therapy

                            France arrow
                            AACR Annual meeting
                            Not Confirmed

                            PEP-Therapy

                            France arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PEP-010

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Italian Angels for Growth

                            Deal Size : $3.5 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            PEP-Therapy Raises €2.75 Million in Series A Financing to Advance Its Lead Candidate, PEP-010, Into the Clin...

                            Details : PEP-Therapy will use the funds to progress the clinical development of PEP-010, PEP-Therapy's lead Cell Penetrating & Interfering Peptide (CP&IP), for the treatment of advanced solid tumors.

                            Product Name : PEP-010

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            April 22, 2021

                            Lead Product(s) : PEP-010

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Italian Angels for Growth

                            Deal Size : $3.5 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            PEP-Therapy

                            France arrow
                            AACR Annual meeting
                            Not Confirmed

                            PEP-Therapy

                            France arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PEP-010

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pep-Therapy and Institut Curie Granted Approval from Ansm to Start First-in-Human Clinical Trial of Pep-010 fo...

                            Details : PEP-010 is a pro-apoptotic agent which has demonstrated anti-tumor efficacy in a number of pre-clinical models and a good safety profile.

                            Product Name : PEP-010

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            March 16, 2021

                            Lead Product(s) : PEP-010

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth